EGF and colorectal carcinoma: In agreement with previous reports, resistance to B-Raf(V600E) inhibitors is exemplified here in CRC HT29 and PTC BcPAP cells by lack of response to PLX4032 under conditions of EGF- or HGF-activated cell growth (Figure 2A).